Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30776827 | 1.00 | TAAR1 (0.63) | TAAR1GAAHTTBACE1KDM4E | |
| SCHEMBL5045977 | 0.98 | TAAR1 (0.61) | TAAR1GAAHTTBACE1KDM4E | |
| SCHEMBL723742 | 0.85 | TAAR1 (0.48) | TAAR1GAAHTTBACE1KDM4E | |
| SCHEMBL3115865 | 0.82 | TAAR1 (0.70) | TAAR1GAAHTTBACE1KDM4E | |
| SCHEMBL1007397 | 0.82 | TAAR1 (0.52) | TAAR1GAAHTTCYP2A13NPSR1 | |
| SCHEMBL28596017 | 0.81 | TAAR1 (0.63) | TAAR1GAAHTTBACE1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28327987 | 0.79 | TAAR1 (0.50) | TAAR1GAAHTTCYP2A13NPSR1 | |
| SCHEMBL11029627 | 0.79 | TAAR1 (0.50) | TAAR1GAAHTTCYP2A13NPSR1 | |
| SCHEMBL5042264 | 0.79 | TAAR1 (0.50) | TAAR1GAAHTTCYP2A13NPSR1 | |
| SCHEMBL24686248 | 0.79 | TAAR1 (0.61) | TAAR1GAAHTTBACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-214932216-U | 2-chlorine-6-fluorobenzyl chloride storage barrel with good sealing performance | 江苏万隆化学有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-102617312-A | Method for preparing 2-chloro-6-fluorobenzaldehyde | DANYANG WANLONG CHEMICAL CO LTD | 2012-08-01 | — | — | CN | claimed |
| US-6137009-A | ADMIXING MONOALKYLAMINE, ALKALI, AND 2-HALO-6-HALO-BENZYL HALIDE; HEATING TO FORM N-ALKYL-2-HALO-6-HALO-BENZYLAMINE AND SALT | SRM CHEMICAL, LTD. CO. (US) | 2000-10-24 | — | — | US | claimed |
| US-4100159-A | REACTING 2,6-DIHALOBENZYL HALIDES WITH A SALT OF ADENINE IN PRESENCE OF ONIUM SALT PHASE TRANSFER CATALYST | MERCK & CO., INC. (US) | 1978-07-11 | — | — | US | claimed |
| JP-57085388-A | — | — | None | — | — | JP | disclosed |
| EP-4587438-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-07-23 | — | — | EP | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025062334-A1 | 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2025-03-27 | — | — | WO | disclosed |
| CN-116178100-B | Dechlorination reduction method for 2-chloro-6-fluorotrichlorobenzyl | 浙江大洋生物科技集团股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-114516844-B | Quinoxaline derivative, preparation method and application | 贵州大学 | 2024-07-19 | — | — | CN | disclosed |
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-4189485-A | ANTICOCCIDIAL ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-02-19 | — | — | US | disclosed |
| US-4171440-A | Process for purification of 9-(2,6-dihalobenzyl)adenines | MERCK & CO., INC. (US) | 1979-10-16 | — | — | US | disclosed |
| EP-0002214-A1 | Benzyl ethers of cyclic 1,2-diols, methods for their preparation and their use as herbicides | BAYER AG (DE) | 1979-06-13 | — | — | EP | disclosed |
| US-4146384-A | Tetrahydrofuran-ether compounds and herbicidal compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-27 | — | — | US | disclosed |
| EP-0000002-A1 | Tetrahydrofurane derivatives, processes for their preparation and their use as herbicides | BAYER AG (DE) | 1978-12-20 | — | — | EP | disclosed |
| US-4127721-A | Derivatives of thiadiazolo[3,4-d]pyrimidine | MERCK & CO., INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4100159-A | REACTING 2,6-DIHALOBENZYL HALIDES WITH A SALT OF ADENINE IN PRESENCE OF ONIUM SALT PHASE TRANSFER CATALYST | MERCK & CO., INC. (US) | 1978-07-11 | — | — | US | disclosed |
| US-4098787-A | Process for preparation of 9-(dihalobenzyl) adenines | MERCK & CO., INC. (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174674-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RET, WEE1, JAK2 | TAAR1 1120/4885GAA 3924/4885HTT 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.